Tools · Private company
Blue Earth Diagnostics
Track this companyFree. Adds Blue Earth Diagnostics to your Dealase workspace and tells you when its record changes.
Clinical trials2525 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- [18F]FPyQCPPhase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- fluciclovine (18F)Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials25
- POSLUMA PET Imaging for PI-RADS 3 Prostate LesionsNA · NOT_YET_RECRUITING · started Dec 1, 2026ClinicalTrials.gov NCT07916311 · fetched Nov 12, 2026
- Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGGEARLY_PHASE1 · RECRUITING · started Nov 29, 2026ClinicalTrials.gov NCT05555550 · fetched Nov 12, 2026
- Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrencePHASE4 · RECRUITING · started Aug 31, 2026ClinicalTrials.gov NCT07569926 · fetched Nov 12, 2026
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTPHASE2 · RECRUITING · started Jul 29, 2026ClinicalTrials.gov NCT07455903 · fetched Nov 12, 2026
- Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer EvaluationPHASE2 · NOT_YET_RECRUITING · started May 1, 2026ClinicalTrials.gov NCT07568756 · fetched Nov 12, 2026
- Androgen-responsive POSLUMA-guided Intra-prostatic BoostPHASE2 · RECRUITING · started Apr 29, 2026ClinicalTrials.gov NCT07393867 · fetched Nov 12, 2026
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsPHASE1_PHASE2 · RECRUITING · started Feb 19, 2026ClinicalTrials.gov NCT07432633 · fetched Nov 12, 2026
- Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active SurveillancePHASE2 · RECRUITING · started Feb 10, 2026ClinicalTrials.gov NCT07285057 · fetched Nov 12, 2026
- Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON TrialEARLY_PHASE1 · RECRUITING · started Nov 14, 2025ClinicalTrials.gov NCT07164027 · fetched Nov 12, 2026
- An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.PHASE2 · RECRUITING · started Oct 9, 2025ClinicalTrials.gov NCT07185165 · fetched Nov 12, 2026
- Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland TreatmentNA · RECRUITING · started Oct 1, 2025ClinicalTrials.gov NCT07011342 · fetched Nov 12, 2026
- Flotufolastat F 18 PET in Men With Very Low PSA RecurrenceRECRUITING · started May 20, 2025ClinicalTrials.gov NCT06862856 · fetched Nov 12, 2026
- PET Scan Study to Detect Prostate Cancer in Patients with Early PSA RecurrencePHASE2 · RECRUITING · started Sep 20, 2024ClinicalTrials.gov NCT06617481 · fetched Nov 12, 2026
- Feasibility of 18F-Fluciclovine PET/CT to Identify Brain MetastasisEARLY_PHASE1 · RECRUITING · started Sep 10, 2024ClinicalTrials.gov NCT06055790 · fetched Nov 12, 2026
- 18F-Fluciclovine PET-MRI in High-grade GliomaEARLY_PHASE1 · RECRUITING · started Aug 7, 2024ClinicalTrials.gov NCT05553041 · fetched Nov 12, 2026
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate CancerPHASE4 · ACTIVE_NOT_RECRUITING · started Jun 30, 2024ClinicalTrials.gov NCT06479187 · fetched Nov 12, 2026
- 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic RadiosurgeryPHASE1 · RECRUITING · started Apr 11, 2024ClinicalTrials.gov NCT06048094 · fetched Nov 12, 2026
- Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CTPHASE1 · RECRUITING · started Feb 1, 2024ClinicalTrials.gov NCT06062745 · fetched Nov 12, 2026
- 18F-FLUC PET/MR in Patients With Brain MetsPHASE3 · RECRUITING · started Jan 10, 2024ClinicalTrials.gov NCT06159335 · fetched Nov 12, 2026
- Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PETPHASE4 · ACTIVE_NOT_RECRUITING · started Oct 4, 2023ClinicalTrials.gov NCT05722925 · fetched Nov 12, 2026
- Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Apr 27, 2023ClinicalTrials.gov NCT05779943 · fetched Nov 12, 2026
- Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical ProstatectomyPHASE3 · ACTIVE_NOT_RECRUITING · started Jan 31, 2023ClinicalTrials.gov NCT05678322 · fetched Nov 12, 2026
- Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain MetastasisPHASE2 · RECRUITING · started Jan 10, 2023ClinicalTrials.gov NCT05554302 · fetched Nov 12, 2026
- Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic RadiosurgeryPHASE1 · RECRUITING · started Apr 4, 2022ClinicalTrials.gov NCT04689048 · fetched Nov 12, 2026
- Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyPHASE2 · RECRUITING · started Sep 30, 2020ClinicalTrials.gov NCT04175431 · fetched Nov 12, 2026